C5 inhibition with eculizumab prevents thrombotic microangiopathy in a case series of pig-to-human kidney xenotransplantation

Jones-Carr et al discuss their study on the histologic outcomes of a series of brain-dead human recipients of a porcine kidney xenotransplant using exclusively FDA-approved medications, with and without anti-C5 monoclonal antibody. Although studies of porcine kidney xenotransplantation in nonhuman p...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of clinical investigation Vol. 134; no. 5; pp. 1 - 3
Main Authors Jones-Carr, Maggie E, Fatima, Huma, Kumar, Vineeta, Anderson, Douglas J, Houp, Julie, Perry, Jackson C, Baker, Gavin A, McManus, Leigh, Shunk, Andrew J, Porrett, Paige M, Locke, Jayme E
Format Journal Article
LanguageEnglish
Published United States American Society for Clinical Investigation 01.03.2024
Subjects
Animals
Antibodies, Monoclonal, Humanized - pharmacology
Antibodies, Monoclonal, Humanized - therapeutic use
Biopsy
Blood clot
Brain death
Case studies
Complications and side effects
FDA approval
Humans
Immune response
Immunosuppression
Kidney
Kidneys
Microcirculation disorders
Monoclonal antibodies
Prevention
Research Letter
Swine
Thrombosis
Thrombotic Microangiopathies - drug therapy
Thrombotic Microangiopathies - prevention & control
Thrombotic microangiopathy
Transplantation
Transplantation, Heterologous
Transplants & implants
Xenografts
Xenotransplantation
United States
Alabama
United States > US
Innate immunity
Nephrology
Complement
Transplantation
Organ transplantation
Online AccessGet full text

Cover

More Information
Summary:Jones-Carr et al discuss their study on the histologic outcomes of a series of brain-dead human recipients of a porcine kidney xenotransplant using exclusively FDA-approved medications, with and without anti-C5 monoclonal antibody. Although studies of porcine kidney xenotransplantation in nonhuman primates (NHPs) and brain-dead humans have improved our understanding of anti-xenograft immune responses (1-3), the optimal immunosuppression regimen for living human recipients is unknown (3). Prior NHP studies suggest that complement plays an important role in immune-mediated injury of xenografts (4), but the benefits of pharmacologic complement inhibition in human xenograft recipients have yet to be established.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1558-8238
0021-9738
1558-8238
DOI:10.1172/JCI175996